Mechanism and Effect of Novel Metabolites on Valvular Heart Disease

Mechanism and Effect of Novel Metabolites on Valvular Heart Disease（Hestia Study）

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07065500

Acronym

Hestia

Enrollment

4000

Registered

2025-07-15

Start date

2025-08-01

Completion date

2030-03-01

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Valvular Heart Disease

Keywords

novel metabolites, valvular heart disease, prognosis, Risk Factors

Brief summary

Valvular heart disease (VHD) is a leading cause of loss of physical function, reduced quality of life and increased longevity.The epidemiology of VHD varies widely across the globe, with functional and degenerative diseases occurring predominantly in high-income countries and rheumatic heart disease occurring predominantly in low- and middle-income countries. The prevalence of valvular heart disease (VHD) is increasing globally due to improved survival and aging populations, poorly controlled by medications, with the majority of patients having to undergo surgical or interventional treatments. It is therefore important to search for novel metabolites and conduct mechanistic studies on the effects of these metabolites on patients with heart valve disease. In the Hestia study, the investigators looked for risk factors and mechanisms associated with the development and prognosis of VHD through long-term follow-up of VHD patients and metabolite testing of specimen tissues.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age ≥18 years, gender is not limited. 2. Clinical diagnosis of heart valve disease (including aortic stenosis, aortic valve closure insufficiency due to different etiologies, mitral stenosis, mitral valve closure insufficiency, pulmonic stenosis, pulmonic valve closure insufficiency, tricuspid stenosis and tricuspid closure insufficiency due to different etiologies )

Exclusion criteria

Patients unable to provide informed consent

Design outcomes

Primary

Measure	Time frame
Number of Participants with All-cause mortality	5 years

Secondary

Measure	Time frame
Number of Participants with cardiovascular events	5 years
Number of Participants with progression of valvular heart disease	5 years

Countries

China

Contacts

Primary ContactXiaodong Zhuang

zhuangxd3@mail.sysu.edu.cn+8613760755035

Outcome results